Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Dexmedetomidine Nasal Spray and Postoperative Recovery After Breast Tumor Surgery
ChiCTR2600116592Phase 4Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine in breast neoplasia (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Postoperative Quality of Recovery Scale (QoR-15) on postoperative day 1. Started Jan 2026; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
breast neoplasia
Beyond the preview
Go deeper on ChiCTR2600116592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116592.